Singapore Infectious Disease Therapeutics Market Insights Forecasts to 2033

• The Singapore Infectious Disease Therapeutics Market Size was valued at USD 151.5 Million in 2023.
• The Market Size is Growing at a CAGR of 4.95% from 2023 to 2033
• The Singapore Infectious Disease Therapeutics Market Size is expected to reach USD 245.5 Million by 2033

The Singapore Infectious Disease Therapeutics Market Size is anticipated to exceed USD 245.5 Million by 2033, growing at a CAGR of 4.95% from 2023 to 2033. The increasing incidence of infectious ailments, increasing expenditure on disease treatment, and product launches are driving the growth of the infectious disease therapeutics market in the Singapore.     

Market Overview

Infectious disease is an illness caused by microscopic organisms or microbes, such as bacteria, viruses, fungi, and parasites. They are mostly communicable diseases that can be spread to people from other people, animals, contaminated surfaces, or insects by consuming or exposure to an infectious organism. In Singapore, infectious diseases remain a serious concern and continue to be a major source of sickness and mortality. Singapore is not immune to the constant threat of pandemics, which is in addition to the predictable burden of endemic diseases like dengue and Candida. Depending on the cause of infectious disease, patients are treated with anti-infective medications, including antibiotics, antiviral, antifungal, and anti-parasitics. These medications either kill or stop the growth of these microorganisms. The growing emphasis on research and development activities for developing infectious disease therapeutics by leading organizations is driving market growth.

Report Coverage

This research report categorizes the market for the Singapore infectious disease therapeutics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Singapore infectious disease therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Singapore infectious disease therapeutics market.

Driving Factors

Infectious disease is the major concern in Singapore with the highest prevalence rate of viral infections, influenza, and respiratory syncytial virus (RSV). Thus, the increasing incidence of infectious ailments is driving the market demand. Singapore's government spends 4.4% of its GDP on healthcare. The increased healthcare spending and initiatives by the Singapore government including the National HIV/AIDS Program and the National Tuberculosis Control Program are significantly contributing to propelling the market growth.

Restraining Factors

The stringent regulatory policies for clinical trials and data submission for drug approval are contributing to challenging the market. Further, the shortage of trained labor and an aging population are contributing to restraining the market.

Market Segmentation

The Singapore Infectious Disease Therapeutics Market share is classified into disease, treatment, and end-use.

• The HIV segment is anticipated to hold the largest market share during the forecast period.

The Singapore infectious disease therapeutics market is segmented by disease into hepatitis, malaria, TB, influenza, HIV, and others. Among these, the HIV segment is anticipated to hold the largest market share during the forecast period. Antiretroviral therapy medicines, also called ART are used for managing HIV. The increasing awareness about viral diseases including human immunodeficiency virus infection and acquired immune deficiency syndrome and the evolving number of R&D in the region are responsible for driving the market growth.

• The antibacterial drugs segment accounted for the largest market share during the forecast period.

The Singapore infectious disease therapeutics market is segmented by treatment into anti-parasitic drugs, antiviral drugs, antifungal drugs, antibacterial drugs, and others. Among these, the antibacterial drugs segment accounted for the largest market share during the forecast period. It was estimated that the number of oral and topical antibiotics prescribed to 3,278,562 patients was 141,944 and 108,357 respectively in the year 2018 to 2021. The growing population & urbanization, development of healthcare infrastructure, and education & awareness campaigns are contributing to driving the market.

• The hospitals segment dominated the Singapore infectious disease therapeutics market with the largest market share during the forecast period.       

Based on the end-use, the Singapore infectious disease therapeutics market is divided into hospitals, clinics, and others. Among these, the hospitals segment dominated the Singapore infectious disease therapeutics market with the largest market share during the forecast period. Hospitals are comprised of a range of clinical, educational, and research activities for the diagnosis, treatment, and prevention of infections. The increasing focus on strengthening infectious disease and management by organizations in the country is contributing to driving the market.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Singapore infectious disease therapeutics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Veredus Laboratories
• Agency for Science, Technology and Research (A*STAR)
• AbbVie Inc.
• Merck and Co.
• Gilead Sciences
• GlaxoSmithKline plc
• Boehringer Inhelheim International GmbH
• Janssen Pharmaceuticals
• Novartis AG
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In July 2023, SCG Cell Therapy, a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, celebrated the official opening of its Cell Therapy cGMP Manufacturing Facility and R&D Centre at its headquarters in Singapore.

Market Segment

This study forecasts revenue at Singapore, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Singapore Infectious Disease Therapeutics Market based on the below-mentioned segments:

Singapore Infectious Disease Therapeutics Market, By Disease

• Hepatitis
• Malaria
• TB
• Influenza
• HIV
• Others

Singapore Infectious Disease Therapeutics Market, By Treatment

• Anti-Parasitic Drugs
• Antiviral Drugs
• Antifungal Drugs
• Antibacterial Drugs
• Others

Singapore Infectious Disease Therapeutics Market, By End-Use

• Hospitals
• Clinics
• Others